비심장성뇌경색의 항혈소판제치료 실패의 예측인자
Predictors of Antiplatelet Treatment Failure in Noncardioembolic Stroke
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The purpose of this study is to identify the differences of risk factors and stroke mechanism between early and late recurrence in patients with long-term antiplatelet therapy for stroke prevention. Methods: We enrolled 114 consecutive patients with recurrent infarction who had been taking antiplatelet agents regularly since previous noncardioembolic cerebral infarction. Total 81 patients (49 men and 32 women) were met to the inclusion criteria through standardized evaluation. Subjects were classified into two groups depending on the time-to-recurrence after antiplatelet therapy: early antiplatelet failure (within 2 years, n=41, hereafter as “EAF”) and later antiplatelet failure (after 2 years, n=40, hereafter as “LAF”). We investigated the differences of clinical factors between two groups using univariate and multivariate analysis. Results: Family history of stroke (29.3% in EAF vs. 10% in LAF, p=0.029) was more frequent in EAF group. Low HDL-cholesterol and High total cholesterol/HDL-cholesterol ratio were associated with the LAF group (p=0.042, 0.005respectively). Multivariate analysis showed that family history of stroke (OR=5.283, 95%CI 1.178-23.699, p=0.030) and previous infarction classified as large artery atherosclerosis (OR=8.497, 95%CI 1.444–50.015, p=0.018) were significant predictors for EAF whereas total cholesterol/HDL-cholesterol ratio (OR=2.002, 95%CI 1.183–3.389, p=0.010) was for LAF. Conclusions: This study suggests that family history of stroke and cerebral infarction due to large artery atherosclerosis are more responsible for the early recurrence while dyslipidemic condition is more related to the late recurrence during long-term antiplatelet therapy in patients with previous cerebral infarction.
Abstract
Background: The purpose of this study is to identify the differences of risk factors and stroke mechanism between early and late recurrence in patients with long-term antiplatelet therapy for stroke prevention. Methods: We enrolled 114 consecutive patients with recurrent infarction who had been taking antiplatelet agents regularly since previous noncardioembolic cerebral infarction. Total 81 patients (49 men and 32 women) were met to the inclusion criteria through standardized evaluation. Subjects were classified into two groups depending on the time-to-recurrence after antiplatelet therapy: early antiplatelet failure (within 2 years, n=41, hereafter as “EAF”) and later antiplatelet failure (after 2 years, n=40, hereafter as “LAF”). We investigated the differences of clinical factors between two groups using univariate and multivariate analysis. Results: Family history of stroke (29.3% in EAF vs. 10% in LAF, p=0.029) was more frequent in EAF group. Low HDL-cholesterol and High total cholesterol/HDL-cholesterol ratio were associated with the LAF group (p=0.042, 0.005respectively). Multivariate analysis showed that family history of stroke (OR=5.283, 95%CI 1.178-23.699, p=0.030) and previous infarction classified as large artery atherosclerosis (OR=8.497, 95%CI 1.444–50.015, p=0.018) were significant predictors for EAF whereas total cholesterol/HDL-cholesterol ratio (OR=2.002, 95%CI 1.183–3.389, p=0.010) was for LAF. Conclusions: This study suggests that family history of stroke and cerebral infarction due to large artery atherosclerosis are more responsible for the early recurrence while dyslipidemic condition is more related to the late recurrence during long-term antiplatelet therapy in patients with previous cerebral infarction.
참고문헌 (29)
- Pulcinelli FM, "Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients", J Am Coll Cardiol, 43, pp.979~984 (2004)
- Ikeda T, "Characterization of the antiplatelet effect of aspirin at enrollment and after 2-year follow-up in a real clinical setting in Japan", Circ J, 74, pp.1227~1235 (2010)
- Adams HP Jr, "Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment", Stroke, 24, pp.35~41 (1993)
- 정부, "재발성 뇌경색의 위험인자에 대한 분석:1개 대학병원 신경과 외래 환자들을 대상으로", 대한신경과학회지, 22(6), pp.598~603 (2004), 대한신경과학회
- Sacco RL, "Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study", Neurology, 44, pp.626~634 (1994)
- "Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration", BMJ, 308, pp.81~106 (1994)
- Alberts MJ, "Antiplatelet effect of aspirin in patients with cerebrovascular disease", Stroke, 35, pp.175~178 (2004)
- Ferguson AD, "Aspirin and clopidogrel response variability: review of the published literature", Tex Heart Inst J, 35, pp.313~320 (2008)
- Fong J, "Predictors of biochemical aspirin and clopidogrel resistance in patients with ischemic stroke", J Stroke Cerebrovasc Dis, 20, pp.227~230 (2011)
- Ridker PM, "A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women", N Engl J Med, 352, pp.1293~1304 (2005)
- Patrono C, "Aspirin resistance: definition, mechanisms and clinical read-outs", J Thromb Haemost, 1, pp.1710~1713 (2003)
- Patrono C, "Aspirin: promise and resistance in the new millennium", Arterioscler Thromb Vasc Biol, 28, pp.25~32 (2008)
- Rocca B, "Determinants of the interindividual variability in response to antiplatelet drugs", J Thromb Haemost, 3, pp.1597~1602 (2005)
- Sweeny JM, "Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements", Nat Rev Cardiol, 6, pp.273~282 (2009)
- Karepov V, "Plasma triglycerides as predictors of platelet responsiveness to aspirin in patients after first ischemic stroke", Cerebrovasc Dis, 26, pp.272~276 (2008)
- Pawelczyk M, "The influence of hyperlipidemia on platelet activity markers in patients after ischemic stroke", Cerebrovasc Dis, 27, pp.131~137 (2009)
- Jood K, "Family History in ischemic stroke before 70 years of age: the Sahlgrenska Academy Study on Ischemic Stroke", Stroke, 36, pp.1383~1387 (2005)
- Szczeklik A, "Relationship between bleeding time, aspirin and the PlA1", A2 polymorphism of platelet glycoprotein IIIa, 2000, pp.110, 965~967
- Angiolillo DJ, "Clopidogrel-statin interaction: myth or reality?", J Am Coll Cardiol, 50, pp.296~298 (2007)
- Lau WC, "Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction", Circulation, 107, pp.32~37 (2003)
- Saw J, "Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial", J Am Coll Cardiol, 50, pp.291~295 (2007)
- Grau AJ, "Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank", Stroke, 32, pp.2559~2566 (2001)
- Kolominsky-Rabas PL, "Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study", Stroke, 32, pp.2735~2740 (2001)
- Lovett JK, "Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies", Neurology, 62, pp.569~573 (2004)
- Yamamoto H, "Mechanisms of second and further strokes", J Neurol Neurosurg Psychiatry, 64, pp.771~776 (1998)
- Krasopoulos G, "Aspirin"resistance" and risk of cardiovascular morbidity: systematic review andmeta-analysis", BMJ, 336, pp.195~198 (2008)
- Snoep JD, "Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis", Arch Intern Med, 167, pp.1593~1599 (2007)
- Xu G, "Recurrence after Ischemic Stroke in Chinese Patients: Impact of Uncontrolled Modifiable Risk Factors", Cerebrovasc Dis, 23, pp.117~120 (2007)
- Toyoda K, "Early Recurrence of Ischemic stroke in Japanese patients: the Japan standard stroke registry study", Cerebrovasc Dis, 24, pp.289~295 (2007)